Selected Publications
Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, Ma J, Patil SL, Langfitt D, Huang S, Cheng C, Klco JM, Gottschalk S, Velasquez MP. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nature Communications Jan 31;13:587, 2022.
Kim-Hoehamer Y-I, Riberdy JM, Zheng F, Park JJ, Shang N, Métais J-Y, Lockey T, Willis C, Akel S, Moore J, Meagher MM, Velasquez MP, Triplett BM, Talleur AC, Gottschalk S, Zhou S.Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Ther Online ahead of print. Jan 8, 2022.
Schreiner P, Velasquez MP, Gottschalk S, Zhang J, Fan Y. Unifying heterogeneous expression data to predict targets for CAR-T cell therapy. OncoImmunology Nov 14;10(1), 2021.
Epperly R, Gottschalk S, Velasquez MP. A bump in the road: How the hostile AML microenvironment affects CAR T cell therapy. Front Oncol Feb 28, 10:262, 2020. doi: 10.3389/fonc.2020.00262. eCollection 2020.
Riberdy JM, Zhou S, Zheng F, Kim YI, Moore J, Vaidya A, Throm RE, Sykes A, Sahr N, Bonifant CL, Ryu B, Gottschalk S, Velasquez MP. The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing. Mol Ther Methods Clin Dev. Jun 30;18:571-581, 2020. doi: 10.1016/j.omtm.2020.06.024. eCollection Sep 11, 2020.
Epperly R, Gottschalk S, Velasquez MP. Harnessing T cells to target pediatric acute myeloid leukemia: CARs, BiTEs, and beyond. Children (Basel) Feb 17;7(2):14, 2020. doi: 10.3390/children7020014.
Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood Jan 4;131(1):30-38, 2018. doi: 10.1182/blood-2017-06-741058. Epub Nov 8, 2017.
Bonifant CL, Velasquez MP, Gottschalk S. Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opin Biol Ther Jan;18(1):51-63, 2018. doi: 10.1080/14712598.2018.1384463. Epub Oct 11, 2017.
Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres DT, Gee A, Heczey A, Gottschalk S. T-cell activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics Sept 2017.
Velasquez MP, Szoor A, Vaidya A, Thakkar A, Nguyen P, Wu M-F, Liu H, Gottschalk S. CD28 and 41BB costimulation enhances the effector function of CD19-specific Engager T cells. Cancer Immunol Res Aug 18, 2017. [Epub ahead of print]
Bonifant CL, Torres, D, Joseph N, Velasquez MP, Szoor A, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. CD123 Engager T cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy 24(9):1615-26, 2016. doi: 10.1038/mt.2016.116
Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriquez-Cruz T, Szoor a, Bonifant CL, Gerken C, Cooper LJN, Song XT, Gottschalk S. T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci Rep 6:27130, 2016. doi: 10.1038/srep27130
Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song X, Gottschalk S. Engager T cells: A new class of antigen-specific T cells that redirect bystander T cells. Molecular Therapy 23(1):171-8. doi: 10.1038/mt.2014.156
Crabtree E, Mariscalco M, Hesselgrave J, Iniguez SF, Hilliard TJ, Katkin JP, McCarthy K, Velasquez MP, Airewele G, Hockenberry MJ. Improving Care for Children with Sickle Cell Disease/ Acute Chest Syndrome. Pediatrics 127(2):e480-8. doi: 10.1542/peds.2010-3099
Velasquez MP, Mariscalco M, Goldstein S, Airewele G. Erythrocytapheresis in children with sickle cell disease and acute chest syndrome. Pediatric Blood and Cancer 53(6):1060-1063, 2009.
Velasquez MP, Moyer Va. Weighing the Evidence: Clinical Practice Guidelines. AAP Grand Rounds 20:51, 2008.
Last update: February 2022